Osteoarthritis Injections in India: A Clinical Reference

What is intra-articular corticosteroid injection used for?

Corticosteroid-class osteoarthritis injections are the most established of the three options, and intra-articular corticosteroid targets an acute osteoarthritis flare directly, reducing joint inflammation and pain within days when oral analgesics and physiotherapy haven't controlled a specific episode. It is the fastest-acting of the three injection classes but the shortest-lasting.

Clinical comparison studies place corticosteroid ahead of hyaluronic acid for early symptom control, typically within the first two to four weeks, with hyaluronic acid closing the gap and often overtaking corticosteroid on pain and function scores by three months. Repeated frequent corticosteroid injection into the same joint carries its own cartilage and infection risk, which is why most protocols space injections months apart rather than repeating on demand.

What does hyaluronic acid (viscosupplementation) injection actually do?

Viscosupplementation replaces lost joint-fluid viscosity with injected hyaluronic acid, a therapy used specifically for knee and hip osteoarthritis where the joint's own synovial fluid has thinned. Effect onset is slower than a steroid, generally over two to four weeks, but multiple systematic reviews report the benefit lasting considerably longer, often into the six-month range.

A 2022 systematic review found hyaluronic acid produced measurable, sustained improvement in pain and function scores across the trials reviewed, though the review also noted meaningful heterogeneity in injection protocol, product formulation and follow-up duration across studies, which is why results vary between trial and clinic. A prospective comparative study directly measuring hyaluronic acid against corticosteroid found the two converge on outcome by around twelve weeks despite a different early trajectory.

Where does platelet-rich plasma actually stand on evidence?

Among the three osteoarthritis injections covered here, PRP is the newest and least standardised. It concentrates a patient's own platelets and reinjects them into the joint, on the theory that growth factors released locally support cartilage and reduce inflammation. Current systematic evidence is insufficient to make a firm recommendation for or against PRP as a standard therapy, a genuinely unsettled position rather than a quiet endorsement.

A retrospective study comparing hyaluronic acid combined with PRP against hyaluronic acid alone, in Grade III and IV knee osteoarthritis specifically, reported better functional outcome with the combination, but the study design was retrospective and the sample modest. This is promising, not settled. A physician recommending PRP-based osteoarthritis injections today is making a judgment call on an evolving evidence base, not applying a guideline consensus, and that distinction matters when counselling a patient on realistic expectations.

What does India's own treatment workflow say?

The Indian Council of Medical Research has published a Standard Treatment Workflow specifically for knee osteoarthritis (ICD-10 M19.9), developed by national orthopaedic experts with explicit attention to what is feasible across different tiers of India's health system, from tertiary centres to rural facilities with limited specialist access. This is the closest thing India has to a national osteoarthritis protocol.

The STW frames injections as one option within a broader non-arthroplasty management pathway that starts with weight management, physiotherapy and oral analgesia before escalating to intra-articular therapy, and surgery only where conservative and injection-based management has genuinely failed. It is written for feasibility at every tier, not just tertiary hospitals, which is precisely why a rural facility with no injection stock still has a defined care pathway to follow.

What are the real risks a consent conversation should cover?

Joint infection (septic arthritis) is the complication every injection protocol exists to avoid, and it is rare when technique is sterile, but it is also the one complication that turns a routine outpatient procedure into an inpatient emergency. Post-injection flare, a transient increase in pain for 24 to 48 hours, is common and self-limiting, and should be distinguished from true infection during patient counselling.

Repeated corticosteroid injection carries a cumulative risk of accelerating cartilage loss, which is the clinical rationale for spacing injections rather than repeating them on a fixed short interval regardless of response. None of this is a reason to withhold a genuinely indicated injection; it is the reason the decision belongs to the treating orthopaedic surgeon, case by case, not a generic schedule.

Why does a hospital's own injection stock matter for continuity of osteoarthritis care?

A patient scheduled for a hyaluronic acid injection who finds the hospital pharmacy out of stock rarely waits for the next batch. The prescription goes to an outside chemist instead, and the follow-up visit that would have caught a complication early, or confirmed the injection actually happened as documented, often doesn't happen at all.

That gap matters more for osteoarthritis injections than for a one-off prescription, because injection therapy is typically a course, not a single event, and continuity across visits is what makes the treatment plan trackable. A hospital that can't guarantee its own hyaluronic acid or corticosteroid stock is effectively outsourcing its osteoarthritis follow-up compliance to whichever chemist the patient happens to walk into.

Medyzen's managed hospital pharmacy services piece covers how reliable in-house stocking is built operationally, the prescription leakage piece covers what a walked-out prescription costs a hospital beyond the single missed sale, and our hospital pharmacy management piece covers the inventory discipline that keeps a course-based therapy like this actually in stock.

Sources

1. 1ICMR Standard Treatment Workflow — Osteoarthritis of Knee Joint — Indian Council of Medical Research
2. 2Role and effectiveness of intra-articular hyaluronic acid in knee osteoarthritis: a systematic review — PMC, National Institutes of Health
3. 3Comparison of intra-articular hyaluronic acid and corticosteroid in knee osteoarthritis: a prospective comparative study — PMC, National Institutes of Health
4. 4Intra-articular hyaluronic acid and PRP versus hyaluronic acid alone in Grade III–IV knee osteoarthritis — PMC, National Institutes of Health
5. 5Standard treatment workflows in orthopedics: an ICMR initiative — Annals of the National Academy of Medical Sciences

This article is a clinical reference for physicians and hospital administrators. It is for informational purposes, is not a substitute for professional medical advice, and contains no dosage or treatment recommendation for patient self-use. Consult a qualified doctor for any individual clinical decision.